

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
09/500,700	02/09/2000	Carlos F. Barbas III	SCRIP1160-4	SCRIP1160-4 2975		
7	7590 08/07/2002					
Lisa A Haile Ph D Gray Cary Ware & Friedenrich LLP 4365 Executive Drive Suite 1100			EXAM	EXAMINER		
			LEFFERS JR,	LEFFERS JR, GERALD G		
San Diego, CA	92121-2133		ART UNIT	PAPER NUMBER		
			1636	99		
			DATE MAILED: 08/07/2002			

Please find below and/or attached an Office communication concerning this application or proceeding.



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
www.usdio.gov

APPLICATION NO./	FILING DATE	FIRST NAMED INVENTOR /	ATTORNEY DOCKET NO.
CONTROL NO.		PATENT IN REEXAMINATION	

EXAMINER				
Gerald G. Leffers Jr.				
ART UNIT	PAPER			
1636	22			

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

## **Commissioner of Patents**

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gerald G. Leffers Jr. whose telephone number is (703)-308-6232. The examiner can normally be reached on Monday through Friday, 9:30 am to 6:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel can be reached at (703) 305-1998. The fax number for the organization where this application or proceeding is assigned is (703) 305-1998.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to **Zeta Adams** whose telephone number is (703) 305-3291.

Gerald G. Leffers Jr., PhD. Examiner, Art Unit 1636

	Application No.	Applicant(s)	
Notice to Comply	09/500,700	BARBAS III ET AL.	
Notice to Comply	Examiner	Art Unit	
	Gerald G. Leffers Jr.	1636	
NOTICE TO COMPLY WITH REQUIREMEN			AINING
NUCLEOTIDE SEQUENCE AND/OR AMINO	ACID SEQUENCE DIS	SCLUSURES	
Applicant must file the items indicated below within the avoid abandonment under 35 U.S.C. § 133 (extension	e time period set the Office ac is of time may be obtained ur	ction to which the Notice order the provisions of 37	e is attached to 7 CFR 1.136(a)).
The nucleotide and/or amino acid sequence disclosure for such a disclosure as set forth in 37 C.F.R. 1.821 - 7			the requirements
1. This application clearly fails to comply with the r directed to the final rulemaking notice published at the effective filing date is on or after July 1, 1998, s 1998) and 1211 OG 82 (June 23, 1998).	t 55 FR 18230 (May 1, 1990)	, and 1114 OG 29 (May	15, 1990). If
<ul><li>2. This application does not contain, as a separate required by 37 C.F.R. 1.821(c).</li></ul>	e part of the disclosure on par	per copy, a "Sequence l	Listing" as
3. A copy of the "Sequence Listing" in computer re 37 C.F.R. 1.821(e).	adable form has not been su	bmitted as required by	
4. A copy of the "Sequence Listing" in computer recomputer readable form does not comply with the attached copy of the marked -up "Raw Sequence I	requirements of 37 C.F.R. 1.	itted. However, the cor 822 and/or 1.823, as in	ntent of the dicated on the
5. The computer readable form that has been filed unreadable as indicated on the attached CRF Disk submitted as required by 37 C.F.R. 1.825(d).	d with this application has bee kette Problem Report. A Sub	en found to be damaged stitute computer readat	d and/or ole form must be
☐ 6. The paper copy of the "Sequence Listing" is not as required by 37 C.F.R. 1.821(e).	the same as the computer re	eadable from of the "Se	quence Listing"
☐ 7. Other: multiple sequences are present in the figure sequence listing or CRF (e.g. figures 8, 9, 17 & 18).	gures that lack sequence ide	ntifiers, are not in the p	paper copy of the
Applicant Must Provide:  ☑ An initial or substitute computer readable form (CF	RF) copy of the "Sequence Li	sting".	
An initial or substitute paper copy of the "Sequence specification.	e Listing", as well as an ame	ndment directing its ent	ry into the
A statement that the content of the paper and corno new matter, as required by 37 C.F.R. 1.821(e) or 1.			oplicable, include
For questions regarding compliance to these	requirements, please co	ontact:	
For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-421	12		
PatentIn Software Program Support Technical Assistance			

To Purchase Patentin Software......703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY